1. Generics Bulletin
  2. >>Business

Strides’ Stelis Moves Closer To EU Nod For Forteo Biosimilar In FY23

Singapore Facility Gets Zero Observations

 
• By Vibha Ravi

Strides’ biopharma arm Stelis Biopharma has moved closer to approval in the EU and likely the US too for a biosimilar to Eli Lilly’s Forteo in FY23, following GMP certification for its manufacturing units. Meanwhile, merchant bankers have been appointed to evaluate strategic options to raise cash for Stelis.

EU Approvals
Strides' First Biosimilar Could Soon Be Approved In EU • Source: Shutterstock

Strides Pharma Science’s biotech arm Stelis Biopharma has moved closer to approval of STLP001 (PTH), a biosimilar to Eli Lilly’s Forteo (teriparatide), in the EU and possibly in the US with positive developments on the manufacturing front.

Two facilities – its flagship Unit 2 in Bengaluru, which offers integrated microbial and mammalian platforms for biologics development and manufacturing and Unit 1, which has a small-scale commercial and clinical batch

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.